REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up

Regeneron’s Q3 2026 adjusted EPS rose 70% year over year to $20.07, beating the $16.08 consensus, while revenue climbed 36% to $5.12B versus $4.55B expected; the article says shares rose in response. Growth came from higher Dupixent profits and demand for Eylea HD and Libtayo, although U.S. legacy Eylea sales fell 41% and combined U.S. Eylea/Eylea HD sales declined 1%. Regeneron raised its 2026 gross-margin outlook to approximately 86% and R&D expense guidance to $6.05B–$6.15B, and its expanded Sanofi deal includes a $1B upfront payment and up to $7B in future milestones.

Analysis

The key read-through is mix quality, not headline growth: Dupixent profit participation and Eylea HD conversion support earnings, but the slight decline in combined U.S. Eylea sales implies the HD launch has not yet demonstrated category-level growth. If that trend persists, share loss to alternatives such as Roche’s Vabysmo may matter more than the legacy-to-HD mix shift. Bayer’s international Eylea economics also face this pressure, although the reported U.S. sales do not establish the same impact on Bayer’s business.

For REGN, the Sanofi upfront payment should boost Q4 reported collaboration revenue but is not a recurring run-rate signal; confirm its earnings and cash-flow treatment before extrapolating the quarter. Higher R&D is a deliberate reinvestment, while the improved gross-margin outlook and lower SG&A guide partially offset near-term expense growth. The $1 billion buyback activity may support demand, but should not substitute for evidence of durable product growth.

Near term, the initial post-results move risks pricing in a clean growth story. Over 1–3 months, the November cemdisiran decision is a binary catalyst; the February 2027 Ordspono decision is a later pipeline checkpoint. Over 6–18 months, the thesis depends on sustained Dupixent economics, Libtayo growth, and Eylea HD stabilizing total franchise sales. The contrarian risk is that strong reported results obscure concentration in collaboration profits and a shrinking Eylea franchise; the upside case is that HD conversion plus newer products makes that decline temporary.

Key Decisions for Investors

• REGN: Prefer adding on a post-earnings pullback rather than chasing the rally. Reassess if subsequent results show combined Eylea sales stabilizing and Dupixent/Libtayo momentum holding; reduce or exit the thesis if combined Eylea weakness deepens or collaboration profit growth rolls over.
• Do not annualize the Q4 Sanofi upfront payment. Track the company’s earnings bridge and cash-flow disclosure to separate one-time recognition from recurring collaboration economics.
• Treat the November 2026 cemdisiran FDA decision as event risk, not a standalone long catalyst: avoid sizing around approval odds without updated regulatory and market expectations. A delay or rejection would weaken the pipeline optionality case.
• Monitor SNY and BAYN as exposure read-throughs, not automatic hedges: the article does not provide enough detail on their broader portfolios or valuation to establish a relative-value trade.